Neurol. praxi. 2024;25(4):322-326 | DOI: 10.36290/neu.2024.035

Acute disseminated encephalomyelitis or multiple sclerosis?

MUDr. Pavel Potužník, Ph.D.1, MUDr. Ing. Radek Tupý, Ph.D.2, MUDr. Eliška Kopáčová1, MUDr. Marek Peterka1, 3
Neurologická klinika, Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova
Klinika zobrazovacích metod, Fakultní nemocnice Plzeň a Lékařská fakulta v Plzni, Univerzita Karlova
Neurologická klinika, Fakultní nemocnice Hradec Králové a Lékařská fakulta v Hradci Králové, Univerzita Karlova

Multiple sclerosis is the most common acquired chronic inflammatory demyelinating disease of the central nervous system. The diffferential diagnosis of multiple sclerosis includes acute disseminated encephalomyelitis, which is a monophasic autoimmune demyelinating disease. Clinically, acute disseminated encephalomyelitis is manifested by encephalopathy and multifocal involvement. In addition to clinical findings, magnetic resonance imaging and cerebrospinal fluid examination can hepl us to differentiate these two entities. This case report describes a rare variant of tumefactive multiple sclerosis, which was initially presented with epileptic seizure and encephalopathy.

Keywords: acute disseminated encephalomyelitis, multiple sclerosis, magnetic resonance imaging, cerebrospinal fluid, ofatumumab.

Received: April 25, 2024; Revised: May 6, 2024; Accepted: May 14, 2024; Published: September 10, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Potužník P, Tupý R, Kopáčová E, Peterka M. Acute disseminated encephalomyelitis or multiple sclerosis? Neurol. praxi. 2024;25(4):322-326. doi: 10.36290/neu.2024.035.
Download citation

References

  1. Buron MD, Chalmer TA, Sellebjerg F, et al. Initial high­‑efficacy disease­‑modifying therapy in multiple sclerosis: a nationwide cohort study. Neurology. 2020;95(8):e1041-e1051. doi: 10.1212/WNL.0000000000010135. Go to original source... Go to PubMed...
  2. Franciotta D, Columba­‑Cabezas S, Andreoni L, et al. Oligoclonal IgG band patterns in inflammatory demyelinating human and mouse diseases. J Neuroimmunol. 2008;200(1-2):125-8. doi: 10.1016/j.jneuroim.2008. 06. 004. Go to original source...
  3. Hauser SL, Bar­‑Or A, Cohen JA, et al. ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. doi: 10.1056/NEJMoa1917246. Go to original source... Go to PubMed...
  4. He A, Merkel B, Brown JWL, et al. Timing of high­‑efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. PMID: 32199096. Go to original source... Go to PubMed...
  5. Hottenrott T, Dersch R, Berger B, et al. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015;12:27. doi: 10.1186/s12987-015-0024-8. Go to original source... Go to PubMed...
  6. Chvojka M, Gut J, Jiránek M. Akutní diseminovaná encefalomyelitida - ADEM. Pediatr. praxi. 2020;21(5):369-373. doi: 10.36290/ped.2020.076. Go to original source...
  7. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune­‑mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler. 2013;19(10):1261-7. doi: 10.1177/1352458513484547. Go to original source... Go to PubMed...
  8. Souhrn údajů o přípravku Kesimpta [Internet]. SÚKL 2021. [cit. 2024-04-21]. Available from: https://prehledy.sukl.cz/prehled_leciv.html#/leciva/0250537.
  9. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing­‑Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021;78(10):1197-1204. doi: 10.1001/jamaneurol.2021.2738. Go to original source... Go to PubMed...
  10. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Go to original source... Go to PubMed...
  11. Uher T, Krasensky J, Malpas C, et al. Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e979. doi: 10.1212/NXI.0000000000000979. Go to original source... Go to PubMed...
  12. Vaněčková M. Nálezy na magnetické rezonanci u neuromyelitis optica a onemocnění jejího širšího spektra. Cesk Slov Neurol N. 2020; 83/116(Suppl1):S20-S30. doi: 10.14735/amcsnn2020S20. Go to original source...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.